Teva Pharmaceutical Industries Limited (TEVA) - מקדם חוב לטווח ארוך להון

The share price history of Teva Pharmaceutical Industries (TEVA) confirms the resilience of a business built on the mass production of affordable generics and the development of unique CNS therapies. Teva Pharmaceutical Industries (TEVA) is overcoming a prolonged downturn, transitioning to a stage of profitable biosimilar development. Massive production scales provide a hedge against severe pricing pressure, and the current metric stands at 1.57, underscoring the holding's significance in global healthcare.

When selecting defensive assets, a low debt-to-equity ratio becomes the priority. Teva Pharmaceutical Industries (TEVA) investments in packaging line automation and AI-driven control reduce costs, which is reflected in the long-term debt-to-equity trend. This metric measures the proportion of loans with a maturity of more than one year, allowing for an assessment of financial leverage stability and the risk of capital freeze.